

Pritchett, Brian PH/US

From: Pritchett, Brian PH/US
Sent: Wednesday, September 07, 2005 11:33 AM
To: Kurys, Barbara PH/US
Subject: HMR2021 US NP - Notice of Allowance memo to inventors

Hello Barbara,

Please note that there was some issues with the IDS and the Supp. IDS. I made a note at the bottom of the page in yellow can't miss it. Let me know how to proceed.

Thanks,
Brian



HMR2021 US PCT -
Notice of All...

INTERNAL MEMORANDUM

Date:	September , 2005
To:	George E. Lee, John G. Jurcak, Timothy A. Ayers
From:	Barbara E. Kurys
Subject:	Notice of Allowance - HMR2021 US PCT
Copies:	Ross J. Oehler

We are pleased to report that we have now received a Notice of Allowance (copy enclosed) in the above-identified US Patent Application. We ask that you consider each of the issues raised below.

Issue Fee

The deadline for payment of the issue fee is three months from the date of mailing, i.e., payment is due on or before **November 30, 2005**. This deadline is non-extendible. Failure to pay the Issue Fee will result in abandonment.

In the absence of instructions to the contrary, we will pay the issue fee on or shortly before the deadline.

Assignment (check as applicable)

The application has been recorded as having been assigned as follows:

Inventors/ Assignors:	George E. Lee John G. Jurcak Timothy A. Ayers
Assignee:	Aventis Pharmaceuticals Inc.
Recorded:	October 10, 2003
Reel/Frame:	014040/0904

Any desired change in Assignment status should be effected before the issue fee is paid, or additional fees will be incurred.

Formal Drawings

Formal drawings are not required.

Examiner's Amendment and Statement for Reasons of Allowance

[Summarize where applicable or state not applicable]

We have the following additional comments.

[Include comments, if any, plus:]

Any amendments or objections must be filed not later than the payment of the issue fee to assure their consideration.

Foreign Priority

Priority has not been claimed.

Please contact us immediately if this is in error.

Domestic Priority

This application is a 371 of PCT/US00/24949 filed September 13, 2000, which claims benefit of 60/229,356, filed September 13, 1999, which is now abandoned.

Please contact us if there is any error *vis-a-vis* domestic priority.

Declaration

We have checked the last rule 1.63 declaration and it appears to be in order.

Claims and Specification

If you believe that any additional claims are desirable, please let us know immediately so we can determine whether the proposed claims are patentable, and whether they are better presented by amendment or by a continuation application.

[We wish to note that the claims were narrowed during prosecution. Specifically, we call your attention to the amendments filed , limiting claim(s) to explain substance of limitation].

Please also check the specification once more for errors.

Continuation/Divisional Applications [as applicable]

We note that claim(s) were canceled during the prosecution of this application **[due to a restriction requirement imposed by the Examiner]**. We should now consider whether the cancelled/non-elected claims should be filed in a continuing/divisional case. Such an application must be filed before the issuance of the "parent case" to establish co-pendency. To ensure co-pendency, we recommend that the continuation/divisional case be filed when the issue fee is paid for the present application. Please contact us before the issue fee due date to discuss whether a continuation/divisional case should be filed.

Duty of Disclosure

According to our records the PTO-1449s enclosed with the IDS filed **August 15, 2005** have been initialed A Supplemental IDS filed **August 25, 2005**, have not been initialed, indicating their review by the Examiner. **[[if not initialed] On , we filed a communication with the PTO to remedy this.** After allowance, additional "material information" will be considered by the PTO only if newly discovered (*e.g.*, through citation by a foreign patent office), and then only by petition.

After payment of the issue fee, the principal recourse is to petition to withdraw the application and then file a continuation under rule 1.53.

Please let us know immediately if you have any information which should be disclosed.

Barbara - Please note that we sent them the IDS on 8/15/05 and the Supp. IDS on 8/25/05 - Yet on the Notice of Allowance they only initialed the 8/15/05 Submission. Should we word the IDS different than is done now. Please let me know your input and I will gladly make amends. Thanks Brian

Best Regards
Barbara E. Kurys

BEK/BSP



UNITED STATES PATENT AND TRADEMARK OFFICE


over for Docket Due Date

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

005487 7590 08/30/2005

ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807



EXAMINER

SACKEY, EBENEZER O

ART UNIT

PAPER NUMBER

1626

DATE MAILED: 08/30/2005

B E K

Des 9/2/05
COMPUTER ENTERED

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,369	12/23/2002	George E. Lee	HMR 2021 US PCT	1765

TITLE OF INVENTION: THIENISOXAZOLE PHENOXY UNSUBSTITUTED ETHYL AND PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$0	\$1400	11/30/2005

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail**

**Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
(571) 273-2885**

or **Fax**

INSTRUCTIONS: This form should be used for transmitting the **ISSUE FEE** and **PUBLICATION FEE** (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

005487 7590 08/30/2005

**ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807**

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/088,369	12/23/2002	George E. Lee	HMR 2021 US PCT	1765
------------	------------	---------------	-----------------	------

TITLE OF INVENTION: THIENOISOXAZOLE PHENOXY UNSUBSTITUTED ETHYL AND PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$0	\$1400	11/30/2005

EXAMINER	ART UNIT	CLASS-SUBCLASS
SACKEY, EBENEZER O	1626	514-217100

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
- (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1	_____
2	_____
3	_____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are enclosed:

- ☐ Issue Fee
- ☐ Publication Fee (No small entity discount permitted)
- ☐ Advance Order - # of Copies _____

4b. Payment of Fee(s):

- ☐ A check in the amount of the fee(s) is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,369	12/23/2002	George E. Lee	HMR 2021 US PCT	1765
005487	7590	08/30/2005		
ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. ROUTE 202-206 MAIL CODE: D303A BRIDGEWATER, NJ 08807				
EXAMINER SACKY, EBENEZER O				
ART UNIT 1626		PAPER NUMBER		
DATE MAILED: 08/30/2005				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 284 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 284 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571) 272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

Notice of Allowability

Application No.

10/088,369

Examiner

EBENEZER SACKEY

Applicant(s)

LEE ET AL.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to amendment filed 06/20/05.
2. ☒ The allowed claim(s) is/are claims 1-77, 80-83, 92-97 and 104-109, now claims 1-93 respectively.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 8/17/05
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☐ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.


JOHANN RICHTER
SUPERVISORY PATENT EXAMINER
GROUP 1000

Complete if Known

Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Eberszer O.
Attorney Docket Number	USHMR2021 - US - PCT

(use as many sheets as necessary)

Sheet	1	of	5	Attorney Docket Number	USHMR2021 - US - PCT
-------	---	----	---	------------------------	----------------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JS		4,075,227		JONES, et. al.	02-21-1978	
		4,085,114		ADACHI, et. al.	04-18-1978	
		4,355,037		STRUPCZEWSKI, et. al.	10-19-1982	
		4,408,053		STRUPCZEWSKI, et. al.	10-04-1983	
		4,408,054		STRUPCZEWSKI, et. al.	10-04-1983	
		4,427,691		SHUTSKE, et. al.	01-24-1984	
		4,452,804		SHUTSKE, et. al.	06-06-1984	
		4,469,669		STRUPCZEWSKI, et. al.	09-04-1984	
		4,504,669		SHUTSKE, et. al.	03-12-1985	
		4,528,376		STRUPCZEWSKI, et. al.	07-09-1985	
		4,644,064		SHUTSKE, et. al.	02-17-1987	
		4,728,851		ONG, et. al.	03-01-1988	
		4,769,472		ONG, et. al.	09-06-1988	
		5,254,595		GUZZI, et. al.	10-19-1993	
		5,321,037		NAGANO, et. al.	08-14-1994	
		5,340,833		BRIDGES, et. al.	08-23-1994	
		5,593,994		BATT, et. al.	01-14-1997	
		5,686,113		PALERMO, et. al.	12-09-1997	
		5,843,940		CULLINAN, et. al.	12-01-1998	
JS		5,856,503		AEBI, et. al.	01-05-1999	

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Ebenezer O.
Attorney Docket Number	USHMR2021 - US - PCT

(use as many sheets as necessary)

Sheet	2	of	5
-------	---	----	---

Attorney Docket Number	USHMR2021 - US - PCT
------------------------	----------------------

[illegible][illegible]

**Examiner
Signature**

Date
Cons

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → 

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **5**

Complete if Known

Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Ebenezer O.
Attorney Docket Number	USHMR2021 - US - PCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ES		ASGHARI, V., et. al., Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes, Molecular Pharmacology Vol. 48, pp. 384-373 (1994)	
		BASSITT, D.P., et. al., Clozapine Efficacy in Tardive Dyskinesia in Schizophrenic Patients, European Archives of Psychiatry and Clinical Neuroscience Vol.248, pp. 209-211 (1998)	
		BENJAMIN, J., et. al., Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking, Nature Genetics Vol. 12, pp. 81-84 (1996)	
		BRYCE, M., et. al., Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrroles: Precursors for the Preparation of Conducting Polymers, Synthetic Metal, Vol. 26, (1988) pp. 153-168	
		CORBETT, R., et. al., Iloperidone: Preclinical Profile and Early Clinical Evaluation, CNS Drug Review Vol.3, No. 2, pp. 120-147 (1997)	
		CRENSHAW, R.R., et. al., Potential Antifertility Agents, 1. Substituted Diaryl Derivatives of Benzo[b]thiophenes, Benzo[b]furans, 1H-2-Benzothiapyrans, and 2H-1-Benzothiapyrans1, Journal of Medicinal Chemistry, Vol. 14, No.12, (1971) pp. 1185-1190	
		CRUZ, C., et. al., Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics, Neuroscience Letters Vol. 231, pp. 1-4, (1997)	
		EBSTEIN, R.E., et. al., Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking, Nature Genetics Vol. 12, (1996) pp. 78-80	
		ELWORTHY, T. R., et. al., N-Arypiperaziny-N-Propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists, Indian Journal of Chemistry - part B Organic Including Medicinal Vol. 40, pp.2674-2687, (1997)	
ES		ERENBERG, G., et. al., Gilles De La Tourette's Syndrome: Effects of Stimulant Drugs, Neurology Vol.35, No. 35, pp.1346-1348, (1985)	

Examiner Signature

Ebenezer O. Sackey

Date Considered

8/25/05

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **5**

Complete if Known

Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Ebenezer O.
Attorney Docket Number	USHMR2021 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>ES</i>		FACTOR, S.A., et. al., The Emerging Role of Clozapine in the Treatment of Movement Disorders, Movement Disorders Vol. 12, No.4 (1997) pp. 483-496	
		FELDPAUSCH, D.L., et. al., The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics Vol. 266, pp.497-508 (1998)	
		FRIEDMAN, J.H., et. al., Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Results of an Open Label for Pilot Study, Clinical Neuropharmacology, Vol. 21, No. 5 pp. 285-288 (1998)	
		GRICE, D.E., et. al., Linkage Disequilibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission-Disequilibrium Test, American Journal of Human Genetics Vol.59, pp.644-652 (1996)	
		HELSLEY, G.C., et. al., Piperidylalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxy piperidyl)ethyl]Indoles, Journal of Medicinal Chemistry, (1978), Vol.21, No.3 pp. 309-312	
		LAHOSTE, G., et. al., Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry Vol. 1, pp. 121-124 (1996)	
		LAHTI, R.A., et. al., Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A [3H]NGD-94-1 Study, Molecular Psychiatry Vol. 3, pp. 528-533 (1998)	
		MAGDO, I., et. al., 3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity, Database Chemabs Online Chemical Abstracts Service, Columbus, Ohio, US	
		RICKETTS, H., et. al., Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat Polymorphism with Parkinson's Disease, Clinical Genetics Vol. 54, pp. 33-38 (1998)	
<i>ES</i>		RUBINSTEIN, M., et. al., Mice Lacking Dopamine D4 Receptors are Supersensitive to Ethanol, Cocaine, and Methamphetamine, Cell, Vol.90, pp. 991-1001 (1997)	

Examiner Signature

Ebenezer O. Sackey

Date Considered

8/25/05

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/088,369
Filing Date	12-23-2002
First Named Inventor	LEE, et. al.
Group Art Unit	1626
Examiner Name	SACKEY, Ebenezer O.
Attorney Docket Number	USHMR2021 - US - PCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ES		SALL, D., et. al., Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure - Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry Vol.40, No. 22, (1997) pp. 3489 - 3493	
		SCHODER, J., et. al., D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 123I-Iodobenzamide Single Photon Emission Computed Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry Vol.43, pp.660-665, (1998)	
		SEEMAN, P., et. al., Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors, Neuropsychopharmacology Vol.16, Iss. 2, pp. 92-135 (1997)	
		SEEMAN, P., et. al., Schizophrenia: Elevation of dopamine D4-like sites, using [3H]Nemonapride and [125I]Epidepride, European Journal of Pharmacology Vol.286 (1995) R3-R5	
		SHIELDS, P.G., et. al., Dopamine D4 Receptors and the Risk of Cigarette Smoke in African-Americans and Caucasians, Cancer Epidemiology, Biomarkers & Prevention Vol. 7, pp.453-458 (1998)	
		VAN TOL, H.M., et. al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Letters to Nature, Vol. 350, 1991, pp 610-614	
		VAN TOL, H.M., et. al., The Dopamine D4 Receptor: A Novel Site for Antipsychotic Action, Clinical Neuropharmacology Vol. 18, No.1 pp. 5143-5153 (1995)	
		VANTOL, H.M., et. al., Multiple Dopamine D4 Receptor Variants in the Human Population, Nature Vol. 358 - 9 (1992) - pp.149 -152	
ES		ZHU, J., et. al., Synthesis of 2-(4-Halogenobenzyl)-3-Arylbenzo[b]-Thiophenes and a 2-(4-Fluorobenzyl)-3-Arylbenzo[b]-Selenophene as Selective Ligands for Antiestrogen-Binding Sites	

Examiner Signature

Ebenezer O. Sackey

Date Considered

8/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.